Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PAM | P19021 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylacetic Acid SCHEMBL28334050 | 0.92 | PAM (0.65) | CYP4Z1ALDH1A1PAMLMNAL3MBTL1 | |
| SCHEMBL68851 | 0.92 | CYP4Z1 (0.62) | CYP4Z1ALDH1A1HSD17B10PAMMAPT | |
| SCHEMBL2308571 | 0.87 | RXRA (0.53) | CYP4Z1MAPTLMNASMN1; SMN2 | |
| SCHEMBL9314768 | 0.86 | LMNA (0.67) | CYP4Z1ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL10299459 | 0.86 | CYP4Z1 (0.57) | CYP4Z1ALDH1A1HSD17B10PAMMAPT | |
| SCHEMBL6057577 | 0.86 | CYP4F2 (0.59) | CYP4Z1ALDH1A1HSD17B10HPGDPAM | |
| SCHEMBL112999 | 0.86 | ALDH1A1 (0.68) | CYP4Z1ALDH1A1PAMMAPTLMNA | |
| SCHEMBL1332625 | 0.86 | ALDH1A1 (0.68) | CYP4Z1ALDH1A1PAMMAPTLMNA | |
| SCHEMBL68930 | 0.86 | CYP4Z1 (0.57) | CYP4Z1ALDH1A1HSD17B10PAMMAPT | |
| SCHEMBL1873977 | 0.86 | ALDH1A1 (0.68) | CYP4Z1ALDH1A1PAMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-113549010-B | Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-116102543-A | GLP-1R agonist, synthesis method and application thereof | 江南大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114230523-A | Benzimidazole derivatives as modulators of ROR-gamma | 生命医药有限责任公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3939974-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-109071509-B | Benzimidazole derivatives as modulators of ROR-gamma | 生命医药有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| EP-3408268-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3383867-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2021-04-14 | — | — | EP | disclosed |
| EP-1708992-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| EP-1179532-B1 | PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR | EISAI R&D MAN CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1708992-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
| US-6573384-B1 | 1,4-substituted cyclic amine compound which is useful as a pharmaceutical, and an intermediate for the process | EISAI CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1179532-A1 | PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR | Eisai Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-0714893-B1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5700819-A | ALDOSE REDUCTASE ENZYME INHIBITOR | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| EP-0714893-A1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | CYP4Z1 1316/4885ALDH1A1 178/4885HSD17B10 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.